In line with this result, pretreatment of several types of cancer cells with MK-2206, a selective AKT1/2/3 inhibitor, blocked EGF-stimulated PFKP expression (Fig. 2d and Supplementary Fig. 2b). Here, PFKP is linked to cancer.